Clinical Trials in Philadelphia

Showing 9041-9060 of 15,860 trials

Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma

NCT03719898

FDA approved drugs to treat patients with relapsed or refractory anaplastic large cell lymphoma (ALCL) has a median progression free survival of 20 months. Majority of patients relapse in 2 years. This study will evaluate overall response rate of next generation ALK inhibitor brigatinib in ALK positive ALCL patients by overcoming mechanisms of resistance to ALK inhibitors on cancer patients.

Anaplastic Large Cell Lymphoma, ALK-Positive

Fox Chase Cancer CenterStarted Dec 2018

Philadelphia, Pennsylvania, United States

COMPLETEDPhase 3< 1 mile

Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)

NCT04292899

The primary objective of this study is to evaluate the efficacy of 2 remdesivir (RDV) regimens with respect to clinical status assessed by a 7-point ordinal scale on Day 14.

COVID-19

Gilead Sciences4,891 participantsStarted Mar 2020

Anaheim, California, United States • Berkeley, California, United States • Burlingame, California, United States +180 more locations

Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma

Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)

Find Trials by Condition in Philadelphia

FES Assisted Cycling in Children With CP

The Effect of Sorafenib on Portal Pressure

Open-label Long Term (52 Weeks) Safety and Tolerability of Agomelatine Sublingual Tablets in Major Depressive Disorder (MDD)

Visual Restoration for Hemianopia

Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder

Safety and Efficacy Study of Guaifenesin and Pseudoephedrine for Symptomatic Therapy to Treat Acute RTI

Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder

Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder

Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD

Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers

Gliogene: Brain Tumor Linkage Study

Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)

A Dose Escalation Study in Solid Tumors and a Dose Expansion Study of PRN1371 in Adult Patients With Metastatic Urothelial Carcinoma

A Study of Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Participants Who Have Experienced CINV(Chemotherapy-Induced Nausea and Vomiting) During the Previous Cycle of Low Emetogenic Chemotherapy (LEC)

Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASH

Topical CP-690,550 For Chronic Plaque Psoriasis

Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia